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Abstract: Psoriasis is a chronic inﬂ  ammatory disorder characterized by T cell dysregulation 
and a chronic inﬂ  ammatory inﬁ  ltrate within the epidermis. Several cytokines play an important 
role in the pathogenesis of psoriasis, including interleukin-12 (IL-12) and IL-23. These cytokines 
act via induction of pro-inﬂ  ammatory cytokines which promote chronic inﬂ  ammation and 
auto-reactivity. Ustekinumab is a fully human monoclonal antibody against the common 
p40 subunit of IL-12 and IL-23. Two randomized, double-blind, placebo-controlled trials of 
ustekinumab have demonstrated signiﬁ  cant and prolonged efﬁ  cacy in the treatment of plaque 
psoriasis. Adverse events were generally similar across treatment and control groups. Studies 
are ongoing to assess the long term safety and efﬁ  cacy proﬁ  les of ustekinumab.
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Introduction
Psoriasis is a chronic systemic inﬂ  ammatory disease which primarily affects the skin 
and joints. The pathogenesis of psoriasis is multifactorial, with genetic, environmental, 
and immunologic factors contributing to the phenotype. Although the inheritance 
pattern for psoriasis remains unclear, a deﬁ  nite genetic predisposition has been noted 
through sibling and twin studies.1,2 Evidence for the role of environmental or external 
factors in psoriasis has been observed clinically by the appearance of psoriatic lesions 
at sites of physical trauma, known as Koebner’s phenomenon. Infections, especially 
streptococcal infections of the upper respiratory tract, have also been recognized as 
triggers of psoriasis.3
Immunologic mechanisms in psoriasis are complex, and are mediated by an aberrant 
T cell response to an unknown pathogen in the skin. The importance of T cells in the 
pathogenesis of psoriasis is supported by the response to treatment with compounds 
that act on lymphocytes, such as cyclosporine.4 In addition, psoriasis may develop 
for the ﬁ  rst time after bone marrow transplantation from a donor with psoriasis.5 
Animal models demonstrate that T cell dysregulation occurs without prior epithelial 
abnormalities, and appears to be dependent upon a susceptible environment.6 The 
cell mediated immune response in the skin of psoriasis patients is thought to be tilted 
toward a T helper-1 (Th1) response with over-expression of pro-inﬂ  ammatory cyto-
kines such as interferon-gamma (IFNγ).7 Several cytokines have been implicated in 
the pathogenesis of psoriasis, including tumor necrosis factor-alpha (TNFα), IFNγ, 
interleukin-12 (IL-12), IL-17 and, more recently, IL-23.
The use of biologic therapies in psoriasis is based on targeting one or more of the 
steps in the cellular immune response. Three fundamental modes of action are being 
explored: decreasing the number of pathogenic T cells, blocking T cell migration and 
adhesion, and inhibiting effector cytokines.8 Current therapies have demonstrated 
clinical efﬁ  cacy; however, several problems exist. First, non-speciﬁ  c suppression 
of T cell function leads to global immune suppression, which underlies many of the Biologics: Targets & Therapy 2009:3 160
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toxicities associated with conventional systemic psoriasis 
treatment. Additionally, long term safety and efﬁ  cacy data for 
recently developed therapies are just becoming available.9,10 
There remains a need for therapies with long term clinical 
efﬁ  cacy and safety proﬁ  les, which would improve patient 
compliance and satisfaction.
Ustekinumab is a fully human monoclonal antibody 
to the shared p40 subunit of IL-12 and IL-23. Studies in 
animal models demonstrated the drug’s ability to block 
IL-12 and IL-23 binding to their receptors, with inhibition of 
downstream signaling. Clinical trials in humans have shown 
ustekinumab to have favorable short term clinical efﬁ  cacy 
and safety proﬁ  les. Long term studies are ongoing.
Immune mechanisms in psoriasis
Current research suggests that the T cells in psoriasis become 
reactive to an unknown antigen in the skin, which results 
in persistent T cell activation and low level expression of 
cytokines and their receptors.11 The cell mediated immune 
response has classically been characterized by the nature 
of inﬁ  ltrating CD4+ T helper (Th) cells, with polarization 
toward a Th1 or Th2 response being dependent upon the 
cytokine milieu and other local factors. The Th1 tilted 
immune response is characterized by a strong cytotoxic 
response directed against intracellular pathogens, whereas 
the Th2 response involves antibody production by B cells.12 
Psoriasis has classically been thought of as a Th1 tilted, 
cell mediated disorder, with inﬁ  ltration of leukocytes into 
the dermis observed before any obvious epidermal changes 
occur.13 T cells play a key role in the pathogenesis of psoriasis 
via induction of an inﬂ  ammatory cytokine cascade, with 
subsequent acceleration of the growth of epidermal and 
vascular cells.14
The ﬁ  rst step in the cellular immune response involves the 
interaction of a naïve T cell with an antigen-presenting cell 
(APC), which leads to T cell activation and differentiation. This 
initial interaction involves the T-cell receptor (TCR) complex 
on the surface of the T cell, which binds speciﬁ  cally to an 
antigen-presenting MHC receptor on the APC. Co-stimulatory 
signals are required for T cell activation. One co-stimulatory 
signal is the interaction of CD40 on APCs with CD40 ligand 
(CD40L) on T cells, which results in the synthesis of high 
levels of the pro-inﬂ  ammatory cytokine IL-12 by mature 
dendritic cells.15,16 IL-12 is the main cytokine in regulating 
the mitotic activation and differentiation of naïve T cells to 
type 1 cells – CD4+ Th1 cells, which can subsequently induce 
clonal expansion of type 1 cytotoxic (Tc1) CD8+ T cells, 
the main effector cell in psoriatic lesions.17 The increased 
expression of IL-12 in psoriatic skin, along with increased 
IL-12 receptor expressed on lesional T cells could drive the 
differentiation to a Type 1 mediated immune response seen 
in both skin lesions and peripheral circulating lymphocytes 
in patients with psoriasis.18,19
IL-12 is also an important regulator of the cell-mediated 
immune response, by inducing the expression of pro-
inﬂ  ammatory cytokines such as IFNγ and TNFα.20 These 
cytokines play a role in the innate immune response via 
stimulation of phagocytic activity, facilitating T cell 
inﬁ  ltration into the epidermis, and inducing keratinocyte 
proliferation.21 IFNγ also may play an important role in 
enhancing survival of keratinocytes, since keratinocytes 
derived from psoriatic plaques were found to be resistant to 
apoptosis compared to normal skin samples.22 Recent studies 
have implicated the importance of IL-23, a newly discovered 
cytokine which shares a common p40 subunit with IL-12, 
in psoriasis. IL-23 acts on different effector cell popula-
tions, including memory T cells and a novel T helper cell 
population, known as Th17 cells.23 Through their elaboration 
of IL-17 and other cytokines important in the inﬂ  ammatory 
response, Th17 cells are thought to have an increasingly 
important role in autoimmune and chronic inﬂ  ammatory 
disorders such as psoriasis.24
IL-12 is a heterodimeric cytokine composed of two 
disulﬁ  de linked subunits, known as p40 and p35.25 While 
p35 is expressed ubiquitously at low levels, p40 expression is 
limited to cells that elaborate IL-12: monocytes, macrophages, 
dendritic cells, neutrophils, and B cells.26,27 IL-12 plays an 
essential role in mediating the innate immune response via 
enhancing the production of pro-inﬂ  ammatory cytokines, 
particularly IFNγ, by natural killer (NK) cells and T cells.28,29 
Other roles of IL-12 include promotion of Langerhans cell 
maturation in the skin, and increasing cytotoxicity of CD8+ 
T cells and NK cells.30 The gene encoding the p40 subunit 
of IL-12 is highly inducible by microbial products such as 
lipopolysaccharide (LPS).31 Therefore IL-12 production 
can be induced in a T cell-independent fashion by cells of 
the innate immune system, as well as by T cell interaction 
with APCs. IFNγ also promotes further IL-12 production, 
potentiating a positive feedback loop.32 Dysregulation of 
any of the steps in this pro-inﬂ  ammatory cascade can lead 
to chronic inﬂ  ammatory changes, as seen in psoriasis and 
other Th1-mediated disorders.
As mentioned above, IL-12 is the key effector cytokine 
in commitment to a Th1 response, which is thought to be 
important in inflammatory and autoimmune conditions. 
However, experiments in mouse models of inﬂ  ammation Biologics: Targets & Therapy 2009:3 161
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have demonstrated that deﬁ  ciency of IL-12 or IFNγ does not 
protect from the development of autoimmune diseases, and 
that often these mice have a more severe clinical picture than 
their wild type counterparts.33 This led to the discovery of 
IL-23, a novel biologically active cytokine which consisted of a 
p19 subunit linked to the p40 subunit of IL-12.34 It is produced 
primarily by activated macrophages and dendritic cells, and 
is thought to play an important role in linking the innate and 
adaptive arms of the immune response.35 Similarly to IL-12, 
IL-23 induces the production of IFNγ by Th1 cells, however 
at a much less efﬁ  cient rate.36 Instead, IL-23 has unique 
cellular targets – memory T cells and a recently discovered 
subset of Th cells, termed Th17 cells because they produce 
IL-17.21 Th17 cells play an important role in the pathogenesis 
of autoimmune and inﬂ  ammatory conditions, and actually 
perform several of the functions originally attributed to IL-12 
and Th1 cells. IL-23 also acts on memory T cells, as evidenced 
by the expression of functional IL-23 receptor on the surface 
of human peripheral blood memory T cells.37 Contrary to 
the role of IL-12 in inducing a Th1 tilted immune response, 
IL-23 may play a more dominant role in maintaining chronic 
inﬂ  ammation in psoriasis and regulating end-stage inﬂ  amma-
tory processes. Further evidence for the role of IL-23 in the 
pathogenesis of psoriasis is supported by repeated intrader-
mal injection of IL-23 in mice, which leads to psoriasis-like 
changes including epidermal hyperplasia and inﬂ  ammation.38 
In human psoriasis lesions, increased expression of IL-23 
subunits compared to healthy controls was noted.39
Cytokine function is dependent upon binding to functional 
receptor on cell surfaces. The IL-12 receptor is composed of 
two subunits, β1 and β2, which form a heterodimer to allow 
high-afﬁ  nity IL-12 binding. The p40 subunit of IL-12 inter-
acts with IL-12Rβ1, whereas p35 binds to IL-12Rβ2, which 
is the subunit involved in signal transduction.40 Expression of 
the β2 subunit of IL-12R on activated T cells and NK cells is 
maintained by IFNγ.41,42 IL-12 receptor is also expressed on 
dendritic cells, forming a positive feedback loop for IL-12 
expression.43 The IL-23 receptor is also composed of two 
subunits: IL-12Rβ1, which is also a subunit of the IL-12 
receptor, and a second subunit which is unique to IL-23, 
known as IL-23R.44 The p40 subunit of IL-23 interacts with 
IL-12Rβ1, whereas the p19 subunit binds to IL-23R. Poly-
morphisms of the human IL-23 receptor complex are asso-
ciated with several autoimmune and inﬂ  ammatory diseases, 
including inﬂ  ammatory bowel disease, psoriasis, and myo-
cardial infarction.45 The IL-23 receptor has been detected 
on the surface of activated and memory T cells, NK cells, 
macrophages, monocytes, and dendritic cells.42,46
Animal models have helped to delineate the unique and 
overlapping functions of IL-12 and IL-23. Mice deﬁ  cient 
in IL-12p40, p35, or IL-12Rβ1 have similar phenotypes of 
decreased IFNγ secretion and NK cell activity, and impaired 
Th1 differentiation.47,48 However, in a mouse model of colitis 
it was noted that p40-/- mice were more immunocompro-
mised than p35-/- mice, owing to the lack of both IL-12 and 
IL-23 in the p40-/- mice.49 IL-12p40-/- mice showed compro-
mised Toxoplasma gondii clearance, which was associated 
with decreased IFNγ production. Subsequent administration 
of IL-23 only prolongs, but does not maintain, viability in 
the IL-12p40-/- mice, suggesting that the presence of IL-23 
cannot fully compensate for the absence of IL-12.50 In terms 
of autoimmune diseases, mice deﬁ  cient in IL-12p40 or 
IL-12Rβ1 were found to be resistant to experimental auto-
immune encephalitis (EAE), a murine model of multiple 
sclerosis, whereas p35 deﬁ  cient mice still develop EAE. In 
addition, IL-12p35 deﬁ  cient mice were noted to have more 
severe phenotypes of autoimmune diseases than their wild 
type counterparts.51 In humans, increased expression of IL-12 
p40 and IL-23p19 was noted in psoriatic skin lesions, whereas 
p35 expression was not increased.52 IL-12p40 appears to be 
critical for the development of autoimmune diseases, since 
knockout mice are resistant, whereas IL-12 itself is dispens-
able – this ﬁ  nding emphasizes the unique role of IL-23 in 
autoimmune inﬂ  ammation.
Th17 cells probably play a role in modulating the normal 
host immune response, as receptors for Th17 cytokines are 
located on epithelial and stromal cell types.53 Evidence for the 
unique role of Th17 cells is supported by the fact that T cells 
producing IL-17 do not produce Th1 or Th2 cytokines.54,55 
Instead, the cytokine proﬁ  le of Th17 cells in humans includes 
IL-17A, IL-17F, IL-22, and IL-6.56 Th17 cytokines were 
found to be more abundant in lesional and non-lesional skin 
of psoriasis patients than in healthy controls.35 Cytokines 
produced by Th17 cells regulate the expression of antimi-
crobial peptides, supporting the role of Th17 in providing a 
link between the adaptive immune response and non-speciﬁ  c 
immunity.57 The differentiation of naïve CD4+ T cells to 
Th17 cells is stimulated in humans by IL-23.35 In humans, 
higher levels of IL-17 producing cells were associated with 
more severe disease in autoimmune conditions such as 
multiple sclerosis and rheumatoid arthritis.58 The function of 
Th17 cells in the skin has been studied in models of psoria-
sis, and this cell lineage was found to play a role in initiat-
ing hyperkeratosis and acanthosis, activating downstream 
inﬂ  ammation, chemotaxis of monocytes and neutrophils, 
T cell migration and activation, and neovascularization.59 Biologics: Targets & Therapy 2009:3 162
O’Neill and Kalb
Th17 cells also produce several cytokines which have been 
implicated in the keratinocyte hyperproliferation response 
in psoriasis, including IL-20 and IL-22.60
IL-23 is an essential cytokine in promoting the develop-
ment of Th17 cells. Mice with EAE and CIA demonstrated 
a correlation between level of IL-23 and development of 
Th17 cells.61 Additionally, mice lacking IL-23 have no Th17 
cells, and were found to be resistant to EAE and CIA.34 This 
link has also been demonstrated in human autoimmune dis-
eases. Patients with Crohn’s disease had a 20-fold increase 
in Th17 cells and IL17+ macrophages compared to healthy 
controls, which the authors concluded may have been due 
to increased IL-23.43,56 Since one of the primary functions of 
Th17 cells is the elaboration of cytokines including IL-17, 
the function of this cytokine has been studied in autoim-
mune and inﬂ  ammatory conditions, including psoriasis. In 
the skin, IL-17 plays a role in regulation of innate immunity 
in keratinocytes by increasing the expression of genes for 
pro-inﬂ  ammatory cytokines and anti-microbial molecules.51 
IL-17 also activates many cell types including dendritic cells, 
macrophages, neutrophils, T cells, and epithelial cells.57
The above ﬁ  ndings support the importance of interleu-
kins-12 and -23 in the pathogenesis of psoriasis. Interfering 
with either or both of these cytokines may prove to be useful 
in psoriasis treatment; however, the implications of blocking 
the actions of these cytokines long term are unknown.
Ustekinumab: a monoclonal 
antibody to the shared p40 subunit 
of IL-12 and IL-23
Clinical trials
Ustekinumab is a novel human monoclonal antibody that 
binds with high afﬁ  nity to the p40 subunit of IL-12 and 
IL-23. The antibody acts to neutralize the bioactivity of these 
cytokines, by blocking interactions with IL-12Rβ1 and pre-
venting subsequent downstream signaling. Inhibition of IFNγ 
production by mitogen-stimulated CD3+ T lymphocytes was 
demonstrated after administration of anti-IL-12p40.62 Previ-
ously known as CNTO-1275, it inhibits the T cell-mediated 
immune response that drives several autoimmune diseases, 
including psoriasis. Ustekinumab is absorbed and eliminated 
slowly; the average half-life was 20 to 24 days, and the drug 
demonstrated linear pharmacokinetics with a dose-dependent 
increase in serum drug concentration.63
Mouse models have demonstrated the potential for 
treatment of autoimmune diseases with antibody directed 
against IL-12p40.64,65 In a marmoset model of EAE, weekly 
injection of CNTO-1275 resulted in delayed and diminished 
symptom development compared to control animals, as well 
as decreased white matter changes by MRI. Additionally, 
disease progression in the setting of pre-existent EAE was 
delayed by treatment with CNTO-1275.66 Neutralizing anti-
body to IL-12p40 also abolished psoriatic lesions in mice.67 
Ustekinumab has also been tested in human autoimmune 
diseases, and has demonstrated efﬁ  cacy in early studies in 
both multiple sclerosis and Crohn’s disease.68,69
The ﬁ  rst phase 1 trial of ustekinumab in psoriasis involved 
18 patients with moderate to severe psoriasis, on an open 
label dose escalation trial with 4 intravenous (IV) doses: 
0.1, 0.3, 1, and 5 mg/kg.70 Study participants had to have 
at least 3% body surface area involvement for inclusion in 
the study. Psoriasis Area and Severity Index (PASI) scores 
were assessed at baseline and during the 16-week follow-up 
period. A sustained and dose-dependent improvement in 
PASI was observed, with 83% of all active treatment group 
patients obtaining an improvement in PASI greater than 50%, 
and 67% of study subjects obtaining a 75% improvement in 
PASI from baseline (PASI 75). Clearing of psoriatic plaques 
was noted as early as two weeks after infusion, and maximal 
beneﬁ  t appeared at 12 weeks for the majority of subjects.
A second phase 1 dose escalation trial of 21 patients 
with plaque psoriasis was a randomized controlled trial of a 
single subcutaneous (SC) injection of ustekinumab versus 
placebo.71 Patients were randomized to receive a SC injec-
tion dose of 0.27, 0.675, 1.35, or 2.7 mg/kg, or placebo. 
The primary endpoint was PASI 75, which was followed 
during the 24-week study. Subjects treated with ustekinumab 
experienced a signiﬁ  cant, dose-dependent improvement in 
symptoms, with 77% of all active treatment subjects obtain-
ing PASI 75 between weeks 4 and 24. PASI 75 was achieved 
in 3 out of 5 subjects in the 0.27 mg/kg group, 4 of 4 in the 
0.675 mg/kg group, 2 of 4 in the 1.35 mg /kg group, and 4 of 
4 in the 2.7 mg/kg group. No subjects in the placebo group 
achieved PASI75. Skin lesions from study participants were 
biopsied at baseline and after 1 week to assess the expression 
of pro-inﬂ  ammatory cytokines in response to treatment with 
ustekinumab. In subjects with sustained PASI improvement 
(deﬁ  ned as at least 70% PASI improvement through week 
16), the expression of IFNγ, IL-8, TNFα, and IL-12p40 and 
IL-23p19 subunits were decreased compared to baseline; 
these changes preceded clinical response and histological 
improvement of lesions.72 Patients who did not achieve 
sustained PASI improvement greater than 70% did not 
demonstrate a decrease in pro-inﬂ  ammatory cytokines at one 
week post-treatment. Interestingly, baseline levels of TNFα Biologics: Targets & Therapy 2009:3 163
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in skin biopsy specimens correlated with clinical response, 
which suggests that this cytokine may be used in the future 
to predict therapeutic responsiveness to ustekinumab.73
A phase II double-blind, placebo-controlled trial of 
320 patients with moderate-to-severe plaque psoriasis was 
also performed by Krueger et al with study subjects ran-
domized to receive 1 of 4 subcutaneous dosing regimens of 
ustekinumab (one 45 mg dose, one 90 mg dose, 4-weekly 
45 mg doses, or 4-weekly 90 mg doses) or placebo.74 Subjects 
with a sub-optimal response received an additional injection 
of the originally assigned dose at week 16, and subjects in the 
placebo group crossed over to receive a single 90 mg injection 
of ustekinumab at week 20. The primary endpoint of the study 
was achievement of PASI 75 at week 12, which was achieved 
in 52%, 59%, 67%, and 81%, respectively, of the aforemen-
tioned groups. In contrast, 2% of subjects who received placebo 
achieved PASI 75, with a p value of 0.001. In addition to 
evaluation of PASI, the physician’s global assessment (PGA) 
was also used in efﬁ  cacy evaluations throughout the 32-week 
study. PGA scores, which were determined by treating physi-
cians and ranged from 1 (clear) to 6 (worse), were signiﬁ  cantly 
better in all active treatment groups versus placebo.
PGA scores were also used to determine which study 
subjects were eligible to receive an additional dose of 
ustekinumab; 37% of patients received one 90 mg dose 
based on PGA scores of 2 or greater at week 16. Study authors 
noted that PGA scores remained relatively stable throughout 
week 24, suggesting that this extra dose did not improve 
clinical outcomes in those patients who did not originally 
respond to ustekinumab. This observation further supports 
the notion that there may be a unique population of respond-
ers to anti-IL-12/23 antibody, possibly deﬁ  ned by baseline 
cytokine proﬁ  les.
Two phase 3 trials were performed to assess long term 
safety and efﬁ  cacy of ustekinumab in large patient cohorts.75,76 
The randomized, double-blind, placebo-controlled trials, 
known as PHOENIX 1 and PHOENIX 2, consisted of nearly 
2000 patients combined, and had similar study designs 
(Figure 1). The PHOENIX 1 study design was SC admin-
istration of 45 mg or 90 mg of ustekinumab at weeks 0 and 
4, then every 12 weeks thereafter. The study was conducted 
in three phases: a placebo-controlled phase (weeks 0–12), 
placebo-crossover and active treatment phase (weeks 12–40), 
and a randomized withdrawal phase (weeks 40–76). During 
the placebo crossover phase, half of study subjects origi-
nally assigned to placebo received 45 mg injections every 
12 weeks, and the other half received 90 mg injections. 
As in previous studies, the primary endpoint was PASI 75, 
which was achieved in approximately 67% of patients in 
both active treatment groups, versus 3% of placebo group 
Figure 1 Study design of PHOENIX 1 and PHOENIX 2 through week 76, which included a placebo-controlled phase (week 0–12), placebo crossover and active treatment 
phase (week 12–40), and randomized withdrawal phase (week 40–76).  In PHOENIX1, subjects who were initially randomized to receive ustekinumab and achieved long term 
response (deﬁ  ned as at least 75% improvement in PASI from baseline) were re-randomized at week 40 to maintenance ustekinumab or withdrawal from treatment until loss 
of response.  In PHOENIX2, partial responders (subjects achieving  50% but  75% improvement in PASI from baseline) were re-randomized at week 28 to continue dosing 
every 12 weeks or escalate to dosing every 8 weeks.
Abbreviations: D/C, discontinued; PASI, psoriasis area and severity index.
45 mg every 12 weeks
Group 2
Group 3
90 mg every 12 weeks
Placebo at weeks 0, 4
Week 28: Week 40: 
PASI < 50: D/C PASI < 75:
:
every 8 weeks 
every 8 weeks  randomized withdrawl 
PASI 75: every 12 weeks 
Week –4 0 12 28 40 76
Screen Placebo-controlled phase  Placebo crossover and active treatment phase  Randomized withdrawal phase Biologics: Targets & Therapy 2009:3 164
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patients (Table 1). Similarly to previous studies, onset of 
efﬁ  cacy was noted by week 2, and maximal efﬁ  cacy was 
observed between weeks 20 and 24. Patients originally 
randomized to placebo achieved similar response rates after 
crossover at week 12. After re-randomization at week 40, time 
to loss of PASI 75 response was better in patients receiving 
maintenance therapy than in the withdrawal of treatment 
group. The median time to loss of PASI75 in patients with-
drawn from treatment was reported as 15 weeks. Rebound 
psoriasis was not reported in patients withdrawn from treat-
ment. Among all active treatment groups, PASI 75 response 
was sustained through week 76.
PHOENIX 2 was similar in design to PHOENIX 1, but 
with dosing intensiﬁ  cation for those subjects who did not 
respond fully to ustekinumab. Partial responders were deﬁ  ned 
as patients who achieved greater than 50% but less than 
75% improvement in PASI scores from baseline. At week 
28, partial responders were re-randomized to continue with 
their current dosing regimen (45 mg or 90 mg ustekinumab 
every 12 weeks), or to increase dosing frequency to every 
8 weeks at their originally assigned dose. Primary endpoint 
results for PHOENIX 2 paralleled PHOENIX 1 results, 
with PASI 75 achieved in 75.7% and 66.7%, respectively, 
of patients in the 90 mg and 45 mg groups. At week 52, 
median improvement in PASI from baseline was around 
95% in all active treatment subjects. There were 93 (22.7%) 
partial responders in the 45 mg group, and 65 (15.8%) in the 
90 mg group. In the 90 mg group, 22 of 33 partial respond-
ers achieved PASI 75 after increasing dosing frequency to 
every 8 weeks. This observation may have been mediated by 
increased serum drug concentration with shortened dosing 
intervals, but does not explain the improvement fully since 
dosing intensiﬁ  cation did not improve clinical outcomes in 
partial responders in the 45 mg group. Subgroup analysis 
of partial responders revealed a tendency toward higher 
bodyweight, more severe disease by PGA, longer duration 
of skin disease, previous failure of biologic agent(s), and 
a higher incidence of psoriatic arthritis. Only higher body 
weight was a statistically signiﬁ  cant predictor of partial 
response to treatment with ustekinumab every 12 weeks. 
In addition, 12.7% of partial responders were found to 
have antibodies to ustekinumab, and serum trough levels 
of ustekinumab at week 28 were 2 to 3 times lower than 
levels in responders.
Adverse events
SC and IV administrations of ustekinumab were generally 
well tolerated, with the majority of adverse events being mild 
in intensity. The most commonly reported adverse events 
included upper respiratory symptoms, headache, arthral-
gias, transient increase in creatine phosphokinase (CPK), 
and lymphopenia. Adverse events were relatively evenly 
distributed across placebo and study groups. Importantly, 
changes in levels of T lymphocyte and NK cell groups were 
noted in early studies but these changes did not appear to be 
consistent or dose-dependent, and did not correlate with any 
clinical symptoms. Injection site reactions were generally 
mild and not considered to be clinically relevant.
Table 1 Improvement in psoriasis area and severity index (PASI) score
Week 12 Week 28
Ustekinumab 
45 mg 
Ustekinumab 
90 mg
Placebo Ustekinumab 
45 mg 
Ustekinumab 
90 mg
Placebo to 
ustekinumab 
45 mg 
Placebo to 
ustekinumab 
90 mg
PHOENIX 1 n = 255 n = 256 n = 255 n = 250 n = 243 n = 123 n = 119
PASI 50 83.5% 85.9% 10.2% 91.2% 96.3% 95.9% 98.3%
PASI 75 67.1% 66.4% 3.1% 71.2% 78.6% 65.9% 84.9%
PASI 90 41.6% 36.7% 2.0% 49.2% 55.6% 44.7% 62.2%
PASI 100 12.5% 10.9% 0.0% 20.8% 29.2% 19.5% 33.6%
PHOENIX 2 n = 409 n = 411 n = 410 n = 397 n = 400 n = 193 n = 194
PASI 50 83.6% 89.3% 10.0% 92.9% 95.0% 93.3% 95.4%
PASI 75 66.7% 75.7% 3.7% 69.5% 78.5% 69.9% 78.9%
PASI 90 42.3% 50.9% 0.7% 44.8% 54.3% 42.5% 51.5%
PASI 100 18.1% 18.2% 0.0% 18.6% 29.5% 15.5% 21.6%
Notes: PASI 50 indicates at least 50% improvement in PASI from baseline. The primary endpoint, PASI 75 at week 12, was statistically signiﬁ  cant in the placebo-controlled 
phase with a p value  0.0001 vs placebo. Placebo crossover occurred at week 12, with study subjects randomized to receive either ustekinumab 45 mg or 90 mg at weeks 
12, 16, and every 12 weeks thereafter, or placebo.Biologics: Targets & Therapy 2009:3 165
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In the phase 2 study, adverse events were high in both 
active treatment and placebo groups (79% and 72%, respec-
tively). Serious adverse events, deﬁ  ned as requiring hospital-
ization, occurred in 4% of patients treated with ustekinumab 
and 1% of patients in the placebo group. Two patients 
receiving ustekinumab were hospitalized for infection, and 
three for cardiovascular events. Contrary to ﬁ  ndings of the 
phase I studies, there were no signiﬁ  cant differences observed 
in changes in absolute lymphocyte counts or lymphocyte 
subsets between treatment and placebo groups. Antibodies to 
ustekinumab developed in 5.1% of phase 3 study participants 
through week 76; these were predominantly low titer and 
not associated with injection site reactions. No anaphylactic 
reactions were observed in either large scale study.
Patients with psoriasis have an increased risk of cardio-
vascular events.77 In the phase 2 trial of ustekinumab two 
patients experienced myocardial infarction and one suffered a 
stroke during the placebo-controlled phase. Subsequent larger 
phase 3 studies revealed no increased risk of cardiovascular 
side effects. One patient in the placebo and group and one 
patient in the active treatment group experienced an adverse 
cardiac event, including a sudden cardiac death in the active 
treatment group.
Since the Th1 response is important for clearance of 
intracellular pathogens and defense against malignancies, 
the incidence of these adverse effects was considered to be 
especially important in the evaluation of ustekinumab.78,79 
During PHOENIX 1 and PHOENIX 2, two serious infections 
occurred during the placebo-controlled phase in patients 
receiving ustekinumab 90 mg, one case each of cellulitis and 
herpes zoster. Patients receiving maintenance ustekinumab 
therapy did not experience increased rates of adverse events 
compared to patients in the randomized withdrawal group.
Patients were screened for tuberculosis (TB) before 
enrollment. Exclusion criteria included symptoms of active 
TB. However patients with a newly identiﬁ  ed positive skin 
test (“latent TB”) could be included if appropriate treatment 
was initiated before or along with ﬁ  rst administration of 
the study agent. No cases of TB, latent reactivation of TB, 
other mycobacterial infections or salmonella infections were 
observed.
Cutaneous malignancies were reported in two patients 
during the placebo-controlled phase of PHOENIX 2, a 
squamous cell cancer in the placebo group and a basal 
cell cancer in the 90 mg treatment group. No differences 
were observed in common laboratory tests between active 
treatment and placebo groups, including liver function tests, 
fasting glucose, or hemoglobin A1c levels.
Although the incidence of serious infections was low in 
studies to date, concern remains for the risk of generalized 
impaired immunity after treatment with ustekinumab, since 
IFNγ and IL-12 are essential for cell mediated immunity. 
Additionally, blocking both IL-12 and IL-23 through their 
common p40 subunit may also impair the Th17 response, 
which is thought to be important in normal keratinocyte 
host immunity.
IL-23 knockout mice were demonstrated to have impaired 
clearance of bacterial and parasitic pathogens, decreased num-
bers of NK cells, and deﬁ  cient Th cell development.80 They 
also have a defect in re-activation of memory T cells, which 
leads to impairment in the humoral immune response and 
delayed type hypersensitivity reactions.81 In human subjects 
suffering from severe mycobacterial and salmonella infec-
tions, defects in the genes encoding IL-12p40 and IL-12Rβ1 
were detected.82,83 These observations suggest continued 
vigilant observation of patients treated with this agent.
Studies to investigate potential limiting factors in the use 
of ustekinumab were performed in monkeys.68 Embryo-fetal 
toxicity studies performed during the period of organogenesis 
did not reveal maternal or fetal abnormalities. Nevertheless, 
study participants to date have been predominantly males, 
since women of childbearing age were excluded from 
participation. Additionally, studies were conducted in a 
monkey model of asthma, which showed that ustekinumab 
did not exacerbate the pulmonary function of study monkeys 
following two IV doses at 50 mg/kg, spaced 4 weeks apart. 
Further research is needed to determine whether these results 
will translate to human subjects.
Conclusion
The above results support the strategy of development 
of monoclonal antibodies directed against Th1 cytokines 
involved in the pathogenesis of autoimmune and chronic 
inﬂ  ammatory responses. Although there are limitations in 
comparison across studies, current data indicate that clinical 
efﬁ  cacy of ustekinumab compares favorably with the high-
est efﬁ  cacy reported for currently available biologic thera-
pies.84,85,86 Additionally, the long half-life of ustekinumab 
allows for prolonged efﬁ  cacy with infrequent dosing sched-
ules, which may improve treatment adherence. Treatment 
with subcutaneous injections of ustekinumab every 12 weeks 
appeared to be efﬁ  cacious for most psoriasis patients, but 
intensiﬁ  cation to every 8 week therapy at 90 mg may be 
necessary to elicit a full response in a subset of patients. 
Partial responders, which could represent approximately 20% 
of the total population, were found to have lower serum drug Biologics: Targets & Therapy 2009:3 166
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levels than PASI 75 responders, indicating an association 
between drug levels and clinical response. Identiﬁ  cation of 
partial responders may be facilitated by demographic char-
acteristics, such as increased body weight or lack of response 
to other biologic agents, or possibly by cytokine proﬁ  les. 
Residual skin disease may be mediated by alternate immune 
pathways in these individuals. In patients withdrawn from 
ustekinumab therapy in phase 3 trials, psoriasis gradually 
recurred, showing that temporary blockade of IL-12 and 
IL-23 did not reverse the underlying causal mechanism of 
psoriasis. Therefore, sustaining clinical response and quality 
of life improvements could require indeﬁ  nite maintenance 
dosing. Current studies did not reveal any major safety 
concerns in blocking IL-12 and IL-23 for up to 18 months; 
however, uncommon events or events that occur after longer 
exposure cannot be excluded based on current study data. 
For this reason, the PHOENIX 1 and PHOENIX 2 studies 
have been extended for a total of 5 years.
It is important to note that serious adverse events may not 
be noted in newly approved medications until post-marketing 
surveillance studies. This may be in part because some serious 
adverse events are very uncommon, and are not detected until 
a drug has been used in a large number of patients. Addi-
tionally, patients participating in clinical trials have speciﬁ  c 
inclusion and exclusion criteria which may not be applicable 
to the general population . A recent study examined the nature 
and frequency of safety-related regulatory actions for biologic 
drugs following approval, including dear health care profes-
sional letters and black box warnings.87 The probability of a 
safety-related regulatory action for a newly approved biologic 
agent was 14% 3 years after approval, and 29% 10 years 
after approval. Additionally, biologics ﬁ  rst in class to obtain 
approval had a higher risk for a safety-related regulatory 
action, with a hazard ratio of 3.7. Therefore, providers and 
patients should be vigilant in monitoring patients being treated 
with ustekinumab, as serious adverse events may only become 
apparent during post-marking surveillance.
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